CK-7 Immunohistochemistry Test in Lahore at Lahore PCR Lab

CK-7 Immunohistochemistry at Lahore PCR Lab

CK-7 (Cytokeratin 7) Immunohistochemistry (IHC) is a highly specialized diagnostic laboratory test performed at Lahore PCR Lab in Lahore, Pakistan. This advanced pathology investigation plays a critical role in modern oncology, surgical pathology, and personalized medicine. Cytokeratins are proteins that form intermediate filaments within the intracytoplasmic cytoskeleton of epithelial cells. Among these, Cytokeratin 7 is a type II, basic-to-neutral cytokeratin, primarily expressed in the simple epithelia lining various cavities, internal organs, ducts, and transitional epithelium. When cells undergo malignant transformation, they typically retain the cytokeratin profile of their tissue of origin. Consequently, evaluating the presence or absence of CK-7 expression in tumor cells provides invaluable diagnostic clues regarding the primary site of a cancer, especially in cases of metastatic tumors of unknown origin.

The CK-7 Immunohistochemistry test works by utilizing highly specific, laboratory-engineered monoclonal antibodies designed to bind exclusively to the CK-7 antigen present in tissue sections. At Lahore PCR Lab, this procedure is conducted on formalin-fixed paraffin-embedded (FFPE) tissue samples obtained through surgical resections, core needle biopsies, or fine-needle aspirations. By applying these antibodies to the tissue and utilizing a specialized visualization system, our pathologists can observe the precise localization of CK-7 under a high-resolution light microscope. The clinical importance of this test cannot be overstated; it is a cornerstone of diagnostic algorithms used to differentiate between various types of carcinomas, such as distinguishing primary lung adenocarcinoma from metastatic colorectal cancer, or classifying ovarian and endometrial malignancies. The primary benefit of this test is its high diagnostic specificity, which prevents misdiagnosis, guides oncologists in selecting the most effective targeted therapies, and ultimately improves patient outcomes.

Clinical Procedure: What to Expect

Patient Preparation

Because CK-7 Immunohistochemistry is an in vitro diagnostic test performed on tissue specimens, there is no direct physical preparation required from the patient on the day of the laboratory analysis itself. However, patients and referring physicians should keep the following preparation guidelines in mind:

• Specimen Submission: If the biopsy or surgical procedure was performed at another facility, patients must submit the formalin-fixed paraffin-embedded (FFPE) tissue block (often referred to as the “paraffin block”) along with the corresponding Hematoxylin and Eosin (H&E) stained glass slides and the original histopathology report to Lahore PCR Lab.
• Clinical History: It is highly recommended to provide a complete clinical history, including previous imaging results, suspected primary tumor sites, and details of any prior chemotherapy or radiation therapy, as this context helps the pathologist interpret the staining patterns.
• Biopsy Preparation: If the biopsy is to be performed at Lahore PCR Lab or an affiliated clinical site, the patient must follow the specific preparation instructions for that particular biopsy procedure (e.g., fasting for an image-guided core biopsy, or stopping blood-thinning medications under medical supervision).

During the Procedure

The laboratory phase of the CK-7 Immunohistochemistry test at Lahore PCR Lab involves a series of highly controlled, automated, and manual steps executed by skilled histotechnologists and evaluated by consultant pathologists:

• Tissue Sectioning: The paraffin block containing the patient’s tissue sample is mounted on a microtome, and extremely thin sections (typically 3 to 4 micrometers thick) are cut and transferred onto specialized, positively charged glass slides to ensure tissue adhesion.
• Deparaffinization and Rehydration: The slides are heated and treated with clearing agents like xylene to remove the paraffin wax, followed by graded alcohols to rehydrate the tissue sections.
• Antigen Retrieval: The formalin-fixation process can mask target antigens. To reverse this, the slides undergo Heat-Induced Epitope Retrieval (HIER) using specialized buffer solutions in a temperature-controlled environment, exposing the CK-7 proteins for antibody binding.
• Antibody Incubation: The tissue sections are incubated with a highly specific primary monoclonal antibody directed against Cytokeratin 7. After washing away unbound antibodies, a secondary detection system (typically conjugated with horseradish peroxidase or alkaline phosphatase) is applied.
• Chromogen Visualization: A chromogenic substrate, such as diaminobenzidine (DAB), is applied to the slide. The enzyme reaction produces a visible, insoluble brown precipitate at the site of CK-7 antigen-antibody binding, which is easily visible under a microscope.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to color the cell nuclei blue, providing cellular contrast. Finally, the slides are dehydrated, cleared, and sealed with a coverslip for permanent storage and microscopic evaluation.

When is a CK-7 Immunohistochemistry Test Performed?

Identifying Primary Tumors in Metastatic Disease

When a patient presents with metastatic cancer—where tumor cells have spread to distant sites like the liver, lungs, bones, or lymph nodes—identifying the original source of the cancer is paramount. Physicians request the CK-7 test as part of an initial immunohistochemical panel to narrow down the primary site. For instance, if a biopsy of a liver lesion shows epithelial malignancy, a positive CK-7 result helps rule out primary hepatocellular carcinoma (which is typically CK-7 negative) and points toward a metastatic adenocarcinoma from the breast, lung, or biliary tract.

Differentiating Lung Adenocarcinoma from Colorectal Cancer

Distinguishing between primary lung adenocarcinoma and metastatic colorectal adenocarcinoma in the lung is a frequent diagnostic challenge. Because these two malignancies require vastly different chemotherapy regimens, an accurate diagnosis is critical. Pathologists utilize the CK-7 test alongside CK-20. A classic profile of CK-7 positive and CK-20 negative strongly supports a diagnosis of primary lung adenocarcinoma, whereas a CK-7 negative and CK-20 positive profile is highly characteristic of colorectal origin.

Evaluating Gynecological and Ovarian Malignancies

In gynecological pathology, the CK-7 test is frequently utilized to classify ovarian tumors and differentiate them from other pelvic or metastatic masses. Primary ovarian epithelial carcinomas, particularly serous, endometrioid, and clear cell carcinomas, exhibit diffuse and strong CK-7 positivity. This staining pattern assists physicians in distinguishing primary ovarian malignancies from metastatic colon cancers, which can mimic ovarian tumors clinically and radiologically but are typically CK-7 negative.

Classifying Urinary Tract and Urothelial Carcinomas

Urothelial carcinomas, which originate in the lining of the urinary bladder, ureters, or renal pelvis, show a distinct immunohistochemical profile. These tumors are characteristically positive for CK-7. When a tumor is located in the pelvis or lower abdomen, determining whether it is of urothelial, prostatic, or colonic origin is vital. A positive CK-7 test, especially when combined with other markers like GATA3 and CK-20, helps confirm a urothelial origin and rules out prostate adenocarcinoma, which is consistently CK-7 negative.

Investigating Thyroid and Salivary Gland Neoplasms

The CK-7 test is also indicated in the evaluation of epithelial tumors of the head and neck, particularly those arising in the thyroid and salivary glands. Papillary thyroid carcinomas and various salivary gland adenocarcinomas (such as mucoepidermoid carcinoma and adenoid cystic carcinoma) show robust cytoplasmic expression of CK-7. Pathologists use this marker to confirm the epithelial nature of these lesions and to differentiate them from mesenchymal tumors or metastatic lesions from other non-epithelial sites.

What Does a CK-7 Immunohistochemistry Test Detect?

The CK-7 Immunohistochemistry test detects the presence, intensity, and distribution of Cytokeratin 7 intermediate filaments within the cytoplasm of epithelial cells. Based on these cellular staining characteristics, the test helps identify and differentiate a wide range of benign and malignant conditions:

• Primary Lung Adenocarcinoma: Characterized by diffuse, strong cytoplasmic CK-7 positivity.
• Breast Ductal and Lobular Carcinomas: Shows consistent, strong cytoplasmic expression of CK-7.
• Ovarian Serous and Endometrioid Carcinomas: Exhibits intense, widespread CK-7 staining.
• Urothelial Carcinoma of the Bladder: Typically demonstrates positive staining for CK-7.
• Cholangiocarcinoma (Biliary Tract Cancer): Shows strong positivity, helping distinguish it from hepatocellular carcinoma.
• Pancreatic Ductal Adenocarcinoma: Characterized by positive CK-7 expression.
• Endometrial Adenocarcinoma: Typically displays strong cytoplasmic CK-7 positivity.
• Thyroid Papillary and Follicular Carcinomas: Shows diffuse positive staining for CK-7.
• Salivary Gland Adenocarcinomas: Demonstrates strong cytoplasmic positivity.
• Thymic Carcinoma: Typically stains positive for CK-7.
• Mesothelioma (Epithelioid Type): Often shows positive CK-7 staining, helping differentiate it from other pleural lesions.
• Paget’s Disease of the Breast: Shows positive staining in the intraepidermal malignant cells.
• Normal Bile Duct Epithelium: Exhibits physiological positive staining.
• Normal Bronchial Epithelium: Shows normal, healthy expression of CK-7.
• Colorectal Adenocarcinoma: Characterized by a negative (or occasionally very focal/weak) CK-7 staining pattern.
• Hepatocellular Carcinoma (Primary Liver Cancer): Typically negative for CK-7, aiding in liver tumor differentiation.
• Prostate Adenocarcinoma: Consistently tests negative for CK-7.
• Renal Cell Carcinoma (Clear Cell Subtype): Often negative or only patchily positive, unlike chromophobe renal cell carcinoma which is positive.
• Squamous Cell Carcinoma of the Lung: Typically negative or shows only focal staining, helping differentiate it from adenocarcinoma.
• Seminoma and Other Germ Cell Tumors: Characteristically negative for CK-7.
• Neuroendocrine Tumors (e.g., Small Cell Lung Carcinoma): Usually negative or shows a dot-like focal positivity, distinct from adenocarcinoma.
• Gastric Adenocarcinoma: Often negative or variable, helping differentiate it from esophageal adenocarcinoma which is frequently positive.
• Normal Intestinal Mucosa: Shows physiological absence of CK-7 expression.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that a cancer diagnosis is a highly stressful period for patients and their families. Therefore, we prioritize both accuracy and efficiency in our histopathology department. The turnaround time for a CK-7 Immunohistochemistry test typically ranges from 3 to 5 working days. This timeframe is necessary to ensure precise tissue processing, optimal antigen retrieval, controlled antibody incubation, and a thorough microscopic review by our consultant pathologists. In complex cases requiring an extended panel of multiple immunohistochemical markers, additional time may be required to formulate a comprehensive diagnostic report.

Once the report is finalized and signed off by the consultant pathologist, patients and their referring physicians are notified immediately via SMS. Reports can be accessed and downloaded securely through the Lahore PCR Lab online portal or mobile application, eliminating the need for unnecessary travel. Physical copies of the reports, along with the stained glass slides and paraffin blocks, can also be collected directly from our main diagnostic center in Lahore.

CK-7 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Lung Tissue	Positive in bronchial epithelial cells; negative in alveolar pneumocytes.	Strong, diffuse cytoplasmic positivity in Lung Adenocarcinoma; negative or weak in Squamous Cell Carcinoma.
Gastrointestinal Tract	Negative in normal colonic and rectal mucosal epithelium.	Negative in Colorectal Adenocarcinoma; positive in Upper GI (Esophageal/Gastric) Adenocarcinomas.
Hepatobiliary System	Positive in bile duct epithelial cells; negative in hepatocytes.	Strongly positive in Cholangiocarcinoma; negative in Hepatocellular Carcinoma.
Gynecological Organs	Positive in endometrial and endocervical glandular epithelium.	Strongly positive in Ovarian Serous Carcinoma and Endometrial Adenocarcinoma.
Urinary Tract	Positive in transitional/urothelial epithelium of the bladder and ureters.	Diffuse cytoplasmic positivity in Urothelial Carcinoma; negative in Prostate Adenocarcinoma.
Breast Tissue	Positive in luminal epithelial cells of ducts and lobules.	Strong, diffuse cytoplasmic expression in Breast Ductal and Lobular Carcinomas.
Thyroid Gland	Positive in follicular epithelial cells.	Diffuse and strong positivity in Papillary Thyroid Carcinoma.
Pancreas	Positive in pancreatic ductal cells; negative in acinar cells.	Strong cytoplasmic positivity in Pancreatic Ductal Adenocarcinoma.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for CK-7 Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists with specialized training in oncopathology and immunohistochemistry.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and timely assistance throughout the diagnostic journey.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict national and international quality control standards, ensuring highly reproducible and reliable test results.
• Professional Reporting: Our diagnostic reports are comprehensive, detailed, and structured to provide clear, actionable information to oncologists and surgeons.
• Modern Diagnostic Approach: We utilize state-of-the-art automated staining platforms that minimize manual errors and optimize antibody binding.
• Comfortable Environment: Our collection centers and main laboratory in Lahore offer a clean, professional, and welcoming environment for all patients.
• Convenient Location: Located centrally in Lahore, our main facility is easily accessible, and we offer extensive sample pick-up services across the city.
• Commitment to Accurate Diagnosis: We understand the critical role of IHC in cancer treatment planning and are dedicated to delivering the highest level of diagnostic precision.